ABN-501

N/A

Report date: 2024/06/27 11:03:58

Base Information

Drug NameABN-501
Drug Alias NameAnti-CLDN3 monoclonal antibody - AbionABN-501α-ABN501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-Claudin-3
TargetsClaudin-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbion Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbion Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A